Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2

Journal of Nuclear Medicine

Volumn 53, Issue 12, 2012, Pages 1872-1877

  Zhao, Dan ^a   Jin, Xiaona ^a   Li, Fang ^a   Liang, Jun ^b   Lin, Yansong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

99mTc 3PRGD2; Differentiated thyroid cancer; Integrin v 3; Refractory; SPECT

Indexed keywords

IODINE 131; PEPTIDE DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; VITRONECTIN RECEPTOR;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DRUG TARGETING; DRUG UPTAKE; ECHOGRAPHY; FEMALE; HORMONE DETERMINATION; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; MEDICAL HISTORY; MOLECULAR IMAGING; NEOVASCULARIZATION (PATHOLOGY); ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOACTIVE IODINE REFRACTORY THYROID CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID METASTASIS; TREATMENT RESPONSE; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING;

ADULT; AGED; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MOLECULAR IMAGING; NEOPLASM METASTASIS; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; THYROID NEOPLASMS; TREATMENT FAILURE;

EID: 84870352005     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.107821     Document Type: Article

References (24)

1. Rivera M, Ghossein RA, Schoder H, et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113:48-56. (Pubitemid 351976385)
2. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260-5268.
3. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100. (Pubitemid 37328796)
4. Zhou Y, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics. 2011;1:58-82.
5. Soldi R, Mitola S, Strasly M, et al. Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882-892. (Pubitemid 29082268)
6. 4 linkers. Mol Pharm. 2009;6:231-245.
7. 18F-AH111585, to determine changes in tumor vascularity after anti-tumor therapy. J Nucl Med. 2009;50:116-122.
8. 4 linkers. Eur J Nucl Med Mol Imaging. 2009;36:1296-1307.
9. 99mTc-NC100692. Acta Radiol. 2010;51:40-46.
10. Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med. 2006;47:1434-1439. (Pubitemid 47544928)
11. 18F-FDG. J Nucl Med. 2008;49:22-29.
12. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
13. Haubner R. αvβ3-integrin imaging: a new approach to characterize angiogenesis? Eur J Nucl Med Mol Imaging. 2006;33(suppl 1):54-63.
14. 18F] galacto-RGD. PLoS Med. 2005;2:e70.
15. 99mTc-labeled cyclic RGD peptides for non-invasive monitoring of tumor integrin avb3 expression. Mol Imaging. 2011;10:386-397.
16. 99mTc-G3-2P4-RGD2 is correlated with integrin expressed on both tumor cells and neovasculature. Bioconjug Chem. 2010;21:548-555.
17. 99mTc-3PRGD in non-human primates. Mol Imaging Biol. 2011;13:730-736.
18. Therasse P, Arbuck GS, Eisenhauer AE, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
19. Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67:501-508.
20. Antonelli A, Ferri C, Ferrari SM, et al. New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol. 2010;2010:921682.
21. Cooper DS, Doherty MG, Haugen RB, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
22. 18F- fluorodeoxyglucose positron emission tomography. Ann Nucl Med. 2009;23:17-23.
23. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53:716-722.
24. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med. 2006;47:2000-2007.